TECregen has appointed Dr Klaas P Zuideveld as CEO.
Zuideveld has over two decades of experience in the pharmaceutical and biotechnology sectors, with areas of expertise including translational strategy, clinical development and global regulatory execution. He was previously CEO of Versameb. Other roles formerly held by Zuideveld include Vice President Pharma Partnerships at Caris Life Sciences and Senior Project Lead at Roche.
He also brings advisory experience to the role through his position as advisor to Bulb Healthcare Solutions and Nucleai.
Over the course of his career, Zuideveld has assisted with key milestones in product development and authorisation, including global approvals and Investigational New Drug (IND) clearances.
The appointment of Zuideveld as CEO will assist significantly in driving the company’s growth in the field of thymus rejuvenation. The company recently completed CHF10m financing led by the Boehringer Ingelheim Venture Fund (BIVF). It also saw the appointment of Dr Bo Rode Hansen as Chairman of the Board.
Hansen said: “Klaas is a highly experienced leader with a proven ability to translate innovative science into rigorous clinical development programmes. As TECregen advances its novel approach to restoring thymic function, his leadership will be instrumental in shaping the company’s development strategy and guiding its transition toward the clinic.”
Zuideveld added: “TECregen’s approach to thymus regeneration addresses a central and underexplored mechanism underlying immune dysfunction. With a strong scientific foundation, an expanding pipeline and committed investor support, the company is well positioned to advance its programmes into clinical development and build a platform capable of delivering durable benefit for patients.”